Conduit Pharmaceuticals Inc. (CDTTW)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Conduit Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Conduit Pharmaceuticals Inc. (CDTTW) has returned 50.91% so far this year and -9.78% over the past 12 months.

Based on dividend-adjusted daily data since Sep 25, 2023, CDTTW's average daily return is +2.00%, while the average monthly return is +8.13%. At this rate, your investment would double in approximately 0.7 years.

Historically, 52% of months were positive and 48% were negative. The best month was Nov 2023 with a return of +266.7%, while the worst month was Dec 2024 at -70.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.

On a daily basis, CDTTW closed higher 29% of trading days. The best single day was Nov 29, 2023 with a return of +421.3%, while the worst single day was Apr 24, 2024 at -59.0%.

Conduit Pharmaceuticals Inc. has an annualized alpha of 12085.41%, beta of 1.03, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 26, 2023.

• This stock participated in 398.10% of S&P 500 Index downside but only 156.20% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CDTTW ranks 48 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Conduit Pharmaceuticals Inc. (CDTTW) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Conduit Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Conduit Pharmaceuticals Inc. was 96.07%, occurring on Dec 31, 2025. The portfolio has not yet recovered.

The current Conduit Pharmaceuticals Inc. drawdown is 94.07%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Conduit Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Conduit Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.